Tag - Myomo

Myomo Reports Fourth Quarter and Full Year 2022 Financial Result

Antonette Ho2023-03-24T16:03:19-04:00Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and full year ended December, 31, 2022. inancial and operational highlights for the fourth quarter of 2022 include the following: Product and total revenues were $4.0 million, up 2% sequentially and similar to the prior year quarter; Revenue units were 101, up 16% sequentially and down 6% compared with the prior year...

MyoPro Approved in Australia by National Disability Insurance Scheme

Antonette Ho2023-02-14T20:02:04-05:00Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced that for the first time, the National Disability Insurance Scheme (NDIS) in Australia approved a MyoPro for a patient with a paralyzed arm. The NDIS aids over 500,000 Australians with disabilities through reimbursement for necessary services and support. The patented MyoPro technology was developed by Myomo in collaboration with researchers at the Massachusetts Institute of Technology and Harvard Medical...

Myomo Appoints Yitzchak Jacobovitz to its Board of Directors

Antonette Ho2023-02-14T19:58:41-05:00Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Yitzchak Jacobovitz as a Class II director effective January 27, 2023, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has six directors. “We welcome Yitz to the Myomo Board of Directors and are gratified that AIGH was the lead investor in our most recent equity offering,” said Paul R. Gudonis,...

Myomo Announces Closing of $6.5 Million Upsized Public Offering

Antonette Ho2023-01-18T01:38:35-05:00Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the closing of its previously announced "best efforts" public offering of 20,000,000 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.325 per share for aggregate gross proceeds of approximately $6.5 million, before deducting placement agent fees and other offering expenses. Read more >>

Myomo Announces Pricing of $6.5 Million Upsized Public Offering

Antonette Ho2023-01-17T00:34:18-05:00Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the pricing of its "best efforts" public offering of 20,000,000 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.325 per share for aggregate gross proceeds of approximately $6.5 million, before deducting placement agent fees and other offering expenses. The closing of the offering is expected to occur on or...

Myomo Receives Order from the Louis Stokes Cleveland VA Medical Center to Support MyoPro Clinical Trial

Ziad2022-11-25T13:59:44-05:00Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced receipt of a $120,000 order for MyoPro® units from Cleveland’s Louis Stokes Veterans Administration (“VA”) Medical Center. The primary objective of this trial is to study the efficacy of the MyoPro in motor learning-based therapy for individuals with chronic stroke (>6 months post event) with severe upper limb motor deficits (Fugl-Meyer for Upper Limb score less than 30),...

Myomo Announces Second Quarter Preliminary Revenue and Record Pipeline Additions

Ziad2022-11-25T13:59:45-05:00Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces preliminary second quarter revenue and provides an update on its pipeline entering the third quarter. Revenue for the second quarter of 2022 is expected to be $3.4 million to $3.6 million, an increase of 10% to 16% compared with the second quarter of 2021. Read more >>

Myomo Reports Progress with China Joint Venture, Receives Partial Payment of Technology License Fee

Ziad2022-11-25T13:59:57-05:00Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, provides an update on the status of its joint venture (“JV”) in China and the associated impact on first quarter 2022 revenue. As of March 31, 2022, a portion of the technology license fee from the JV Company, Jiangxi Myomo Medical Assistive Appliance Co. Ltd., has been paid. The Company received $1.0 million of the total $2.7 million license fee...

Myomo Strengthens Intellectual Property Portfolio With Receipt of Key Patent in Japan

Ziad2022-11-25T13:59:58-05:00Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces the granting of patent number 6998478 titled “Powered Orthotic Device and Method of Using Same” by the Japanese Patent Office. This new Japanese patent is part of a family of patents Myomo has been issued for its MyoPro device in the United States, Europe, China and Japan. This family of patents covers a powered orthotic device that supports movement...

Independent Research with Myomo’s MyoPro® Shows Clinically Significant Gains in Motor Function in Individuals with Chronic Moderate-to-Severe Arm Weakness

Ziad2022-11-25T13:59:58-05:00Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that new research measuring the benefits of the Company’s MyoPro myoelectric orthosis found “statistically significant improvements” in a number of motor function measurements. The research study, titled “Myoelectric Arm Orthosis in Motor Learning-Based Therapy for Chronic Deficits After Stroke and Traumatic Brain Injury,” was funded by the U.S. Army Medical Research Acquisition Activity, and supported by the Office of...